105 related articles for article (PubMed ID: 9443629)
1. Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate.
Lai BT; Gao JP; Lanks KW
Cancer Chemother Pharmacol; 1998; 41(2):155-60. PubMed ID: 9443629
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells.
Wang F; Jiang X; Yang DC; Elliott RL; Head JF
Anticancer Res; 2000; 20(2A):799-808. PubMed ID: 10810357
[TBL] [Abstract][Full Text] [Related]
3. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.
Beyer U; Rothern-Rutishauser B; Unger C; Wunderli-Allenspach H; Kratz F
Pharm Res; 2001 Jan; 18(1):29-38. PubMed ID: 11336350
[TBL] [Abstract][Full Text] [Related]
4. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
[TBL] [Abstract][Full Text] [Related]
5. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy.
Kratz F; Beyer U; Roth T; Tarasova N; Collery P; Lechenault F; Cazabat A; Schumacher P; Unger C; Falken U
J Pharm Sci; 1998 Mar; 87(3):338-46. PubMed ID: 9523988
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate.
Lemieux P; Pagé M
Anticancer Res; 1994; 14(2A):397-403. PubMed ID: 8017839
[TBL] [Abstract][Full Text] [Related]
7. Transferrin directed delivery of adriamycin to human cells.
Singh M; Atwal H; Micetich R
Anticancer Res; 1998; 18(3A):1423-7. PubMed ID: 9673350
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells.
Fritzer M; Szekeres T; Szüts V; Jarayam HN; Goldenberg H
Biochem Pharmacol; 1996 Feb; 51(4):489-93. PubMed ID: 8619895
[TBL] [Abstract][Full Text] [Related]
9. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
Szwed M; Kania KD; Jozwiak Z
Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model.
Kratz F; Roth T; Fichiner I; Schumacher P; Fiebig HH; Unger C
J Drug Target; 2000; 8(5):305-18. PubMed ID: 11328658
[TBL] [Abstract][Full Text] [Related]
11. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
Szwed M; Jozwiak Z
Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors.
Szwed M; Kania KD; Jozwiak Z
Int J Biochem Cell Biol; 2016 Jan; 70():57-67. PubMed ID: 26520467
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by doxorubicin-transferrin conjugate compared to free doxorubicin in the human leukemia cell lines.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Chem Biol Interact; 2014 Sep; 220():140-8. PubMed ID: 24998637
[TBL] [Abstract][Full Text] [Related]
15. Differences in the intracellular fate of free and polymer-bound doxorubicin.
Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.
Łubgan D; Jóźwiak Z; Grabenbauer GG; Distel LV
Cell Mol Biol Lett; 2009; 14(1):113-27. PubMed ID: 18850074
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
18. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells.
Fritzer M; Barabas K; Szüts V; Berczi A; Szekeres T; Faulk WP; Goldenberg H
Int J Cancer; 1992 Oct; 52(4):619-23. PubMed ID: 1399145
[TBL] [Abstract][Full Text] [Related]
20. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
